1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Orphazyme A/S

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2009

Location

Copenhagen Denmark

Primary Industry

Biotechnology

About

Based in Herlev, Denmark, and founded in 2009, Orphazyme A/S operates as a biotechnology company that develops therapies for the treatment of lysosomal storage and protein misfolding diseases such as Inclusion Body Myositis (sIBM), Amyotrophic Lateral Sclerosis (ALS), Niemann Pick Type C (NPC), and Gaucher. The firm was listed on Nasdaq Copenhagen in 2017 and is trading under the ticker symbol, ORPHA. In November 2017, Orphazyme raised EUR 80 million in PIPE funding led by investors Kuma Partners, Sunstone Life Science Ventures, Life Sciences Partners, etc. Further, in May 2022, the business was acquired by KemPharm for USD 12.8 million in cash and USD 5.2 million in liabilities. The firm as of January 2024, is led by its CEO, Jakob Bendtsen.
Current Investors
Heartcore Capital, Novo Holdings, Novo Holdings

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.orphazyme.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.